What do you Know about Weight Loss Medications?

Article

Weight loss is essential to arrest the cardiovascular disease and metabolic dysfunction linked to obesity. What do you know about the drugs now available that may help?

With overweight and obesity reaching epidemic levels in the United States and the strong association between excess adiposity and cardiovascular disease, weight loss is recommended by professional societies as part of a heart health plan for at-risk patients. Weight-loss drugs are a valuable part of that plan when used appropriately. How much do you know about dosage, interactions, and safety warnings? Take this quiz and find out!

Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Overweight and Obesity: One Expert's 3 Wishes for the Future of Patient Care
Donna H Ryan, MD Obesity Expert Highlights 2021 Research Success and Looks to 2022 and Beyond
"Obesity is a Medically Approachable Problem" and Other Lessons with Lee Kaplan, MD, PhD
Related Content
Once-Monthly Maridebart Cafraglutide Produces Up to 20% Weight Loss in Phase 2 Trial

Once-Monthly Maridebart Cafraglutide Produces Up to 20% Weight Loss in Phase 2 Trial

Sydney Jennings
June 26th 2025
Article

ADA 2025: Once-monthly dosing led to significant weight loss in adults with obesity, with or without type 2 diabetes, reported researchers.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Sydney Jennings
August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Mifepristone Reduced HbA1c, Body Weight in Adults with Hypercortisolism and Inadequately Controlled T2D: CATALYST Trial Treatment Phase

Mifepristone Reduced HbA1c, Body Weight in Adults with Hypercortisolism and Inadequately Controlled T2D: CATALYST Trial Treatment Phase

Sydney Jennings
June 24th 2025
Article

ADA 2025: Mifepristone lowered HbA1c levels by about 1.5% over 24 weeks vs placebo among participants with hypercortisolism and inadequately controlled T2D.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings
June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Orforglipron, an Investigational Oral GLP-1, Cuts HbA1c and Body Weight in People With T2D

Orforglipron, an Investigational Oral GLP-1, Cuts HbA1c and Body Weight in People With T2D

Sydney Jennings
June 23rd 2025
Article

ADA 2025: Orforglipron lowered HbA1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as 4 weeks, in a phase 3 trial.

Primary Care-Led Weight Management Intervention Prevents Weight Gain and Enhances Revenue: New Research

Primary Care-Led Weight Management Intervention Prevents Weight Gain and Enhances Revenue: New Research

Sydney Jennings
June 23rd 2025
Article

ADA 2025: An intervention to emphasize weight-related care in primary care settings eliminated weight gain at the population level, researchers report.

© 2025 MJH Life Sciences

All rights reserved.